Universal Beteiligungs und Servicegesellschaft mbH Purchases 21,011 Shares of Bruker Corporation $BRKR

Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Bruker Corporation (NASDAQ:BRKR) by 3.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 573,164 shares of the medical research company’s stock after purchasing an additional 21,011 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.38% of Bruker worth $18,622,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its holdings in Bruker by 377.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after buying an additional 487 shares during the period. Huntington National Bank raised its holdings in shares of Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 645 shares in the last quarter. Spire Wealth Management purchased a new stake in Bruker in the second quarter worth $32,000. Parallel Advisors LLC boosted its holdings in Bruker by 63.0% in the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 347 shares in the last quarter. Finally, True Wealth Design LLC boosted its holdings in Bruker by 16,716.7% in the second quarter. True Wealth Design LLC now owns 1,009 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 1,003 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on BRKR shares. Wells Fargo & Company upped their price objective on shares of Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Zacks Research raised shares of Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. Guggenheim raised their price objective on shares of Bruker from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Redburn Partners set a $60.00 price objective on Bruker in a research report on Thursday, November 20th. Finally, Citigroup upped their target price on Bruker from $40.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $53.36.

Insider Buying and Selling at Bruker

In other news, Director John A. Ornell sold 6,233 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the sale, the director directly owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. This represents a 15.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $49.20, for a total value of $98,400.00. Following the transaction, the vice president owned 128,443 shares of the company’s stock, valued at $6,319,395.60. The trade was a 1.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 15,233 shares of company stock worth $726,487 over the last three months. Corporate insiders own 27.30% of the company’s stock.

Bruker Trading Down 3.4%

NASDAQ:BRKR opened at $50.33 on Friday. The firm has a market capitalization of $7.65 billion, a P/E ratio of -314.56, a PEG ratio of 6.85 and a beta of 1.17. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91. Bruker Corporation has a one year low of $28.53 and a one year high of $59.40. The company’s 50-day simple moving average is $48.08 and its 200 day simple moving average is $40.35.

Bruker (NASDAQ:BRKR) last released its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The firm had revenue of $860.50 million during the quarter, compared to analyst estimates of $847.40 million. During the same period last year, the business earned $0.60 earnings per share. The business’s revenue was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, analysts forecast that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Shareholders of record on Monday, December 8th were paid a dividend of $0.05 per share. The ex-dividend date was Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s payout ratio is presently -125.00%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.